Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SonoFIRST
2024-511880-27-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2024
- Modality
- Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of temozolomide, perflutren lipid microspheres and lomustine in glioblastoma (GBM) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Progression-Free Survival (PFS). Planned start Dec 2024; status: authorised.
02
Drugs
temozolomideperflutren lipid microsphereslomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-511880-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511880-27-00.